AccurKardia's Aortic Valve Stenosis Software Enters FDA's TAP Pilot
Event summary
- AccurKardia's AK-AVS™ aortic valve stenosis screening software accepted into FDA's Total Product Life Cycle Advisory Program (TAP) pilot in June 2026.
- AK-AVS received FDA Breakthrough Device Designation in October 2024 and is designed to identify moderate to severe aortic valve stenosis using 12-lead ECG data.
- AccurKardia now has two Breakthrough-designated devices in the TAP pilot, with AK+ Guard™ accepted in January 2025.
- AK-AVS flagged AVS patients up to 4.5 years before treatment in a study conducted at Baylor St. Luke’s Medical Center.
The big picture
AccurKardia's acceptance into the FDA's TAP pilot for its second Breakthrough-designated device underscores the growing regulatory recognition of ECG-based diagnostics. The move aligns with broader industry trends toward earlier disease detection and resource optimization in cardiology, particularly for conditions like aortic valve stenosis that are often underdiagnosed until advanced stages. The company's focus on leveraging existing ECG data for multiple high-burden conditions positions it at the forefront of a shift toward more efficient, data-driven diagnostic pathways.
What we're watching
- Regulatory Momentum
- Whether the FDA's TAP pilot will accelerate AK-AVS's path to market and enable earlier reimbursement discussions with CMS.
- Clinical Adoption
- The pace at which cardiology teams integrate AK-AVS into routine ECG analysis to prioritize echocardiography for high-risk patients.
- Pipeline Expansion
- How AccurKardia's strategy of transforming the ECG into a broad biomarker will impact its pipeline of diagnostic tools beyond AVS and hyperkalemia.